Cargando…

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder

INTRODUCTION AND AIMS: There is increasing interest and evidence for the use of cannabinoid medications in the treatment of cannabis use disorder, but little examination of the correlates of successful treatment. This paper is a secondary analysis of a randomised placebo-controlled trial of nabiximo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mills, Llewellyn, Dunlop, Adrian, Montebello, Mark, Copeland, Jan, Bruno, Raimondo, Jefferies, Meryem, Mcgregor, Iain, Lintzeris, Nicholas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548192/ https://www.ncbi.nlm.nih.gov/pubmed/36209081 http://dx.doi.org/10.1186/s13011-022-00493-z

Ejemplares similares

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol
por: Bhardwaj, Anjali K., et al.
Publicado: (2018)

The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
por: Jackson, Melissa A., et al.
Publicado: (2021)

Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)
por: Lintzeris, Nicholas, et al.
Publicado: (2022)

Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016–2019
por: Black, Emma, et al.
Publicado: (2022)

Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey
por: Suraev, Anastasia, et al.
Publicado: (2023)

Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)
por: Lintzeris, Nicholas, et al.
Publicado: (2020)

Driving-related behaviors, attitudes, and perceptions among Australian medical cannabis users: results from the CAMS 20 survey
por: Arkell, Thomas R., et al.
Publicado: (2023)

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial
por: Trigo, Jose M., et al.
Publicado: (2018)

Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
por: Kanaan, Ahmad Seif, et al.
Publicado: (2017)

LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence
por: Ezard, Nadine, et al.
Publicado: (2018)

Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials
por: Arkell, Thomas R., et al.
Publicado: (2021)

Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence
por: Ezard, Nadine, et al.
Publicado: (2016)

Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity
por: Gajofatto, Alberto, et al.
Publicado: (2023)

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma
por: Twelves, Chris, et al.
Publicado: (2021)

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition
por: Arkell, Thomas R., et al.
Publicado: (2019)

Internet-Delivered Tobacco Treatment for People Using Cannabis: A Randomized Trial in Two Australian Cannabis Clinics
por: Hindson, Josephine, et al.
Publicado: (2020)

Detection of Δ(9) THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices
por: Arkell, Thomas R., et al.
Publicado: (2019)

Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study
por: Ezard, Nadine, et al.
Publicado: (2021)

Prescribing medicinal cannabis
por: Arnold, Jonathon C, et al.
Publicado: (2020)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
por: D’hooghe, Marie, et al.
Publicado: (2021)

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)
por: Mersiades, Antony J, et al.
Publicado: (2018)

Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
por: Schwittay, Maximilian A., et al.
Publicado: (2021)

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis
por: Birke, Rüdiger, et al.
Publicado: (2022)

Nabiximols effect on blood pressure and heart rate in post-stroke patients of a randomized controlled study
por: Rosa, Gian Marco, et al.
Publicado: (2022)

Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile
por: Swift, Wendy, et al.
Publicado: (2013)

Client-level predictors of treatment engagement, outcome and dropout: moving beyond demographics
por: Youn, Soo-jeong, et al.
Publicado: (2019)

Cannabis treatment outcomes among legally coerced and non-coerced adults
por: Copeland, Jan, et al.
Publicado: (2007)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study
por: Pau, Massimiliano, et al.
Publicado: (2022)

A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
por: Chisari, Clara Grazia, et al.
Publicado: (2023)

Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community
por: Suraev, A., et al.
Publicado: (2018)

Opioid prescribing in Australia: too much and not enough
por: Dunlop, Adrian J, et al.
Publicado: (2021)

Commercial Client's Guide to Engaging an Architect
por: Ostime, Nigel
Publicado: (2019)

Domestic Client's Guide to Engaging an Architect
por: Ostime, Nigel
Publicado: (2019)

Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines
por: Lintzeris, Nicholas, et al.
Publicado: (2018)

Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community
por: Suraev, A., et al.
Publicado: (2018)

The “Next Day” Effects of Cannabis Use: A Systematic Review
por: McCartney, Danielle, et al.
Publicado: (2023)

The CANNA-TICS Study Protocol: A Randomized Multi-Center Double-Blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders
por: Jakubovski, Ewgeni, et al.
Publicado: (2020)

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic
por: Dunlop, Adrian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bbhg624bep3ihn6f52p0o8v3de